AMINO ACID RECEPTORS AND BASAL GANGLIA FUNCTION

氨基酸受体和基底神经节功能

基本信息

  • 批准号:
    6112457
  • 负责人:
  • 金额:
    $ 18.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-01-01 至 1999-12-31
  • 项目状态:
    已结题

项目摘要

The basal ganglia play a major role in the control of normal movement and coordination. Lesions of the basal ganglia result in movement disorders ranging from severe akinesia, rigidity and tremor to dystonia, chorea and ballismus. The symptomatology in any particular individual or disease process depends on the distinct subgroups of neurons affected. The neurochemical and functional anatomy of the basal ganglia are now being worked out in detail. The amino acid neurotransmitters appear to mediate neurotransmission at a majority of basal ganglia synapses. The inhibitory amino acid, GABA, is the neurotransmitter for the vast majority of striatal, pallidal and substantia nigra neurons. Excitatory amino acids, (EAA) such as glutamate serve as the neurotransmitters for cortical and thalamic efferents to striatum, subthalamic nucleus and substantia nigra neurons. The subtypes of GABAA and EAA receptors have unique pharmacologies and signal transduction properties. Furthermore, the genes for many of these receptor subtypes have been cloned. Circumstantial evidence suggests that the striatal neurons most vulnerable in Huntington's disease express more NMDA and metabotropic EAA receptors than other striatal neurons. This hypothesis will be tested using double-label in situ hybridization of oligonucleotide probes for these receptors and immunohistochemistry of antibodies directed against the receptor proteins. In previous studies we have found that the different subtypes of GABAA and EAA receptors regulate specifically in response to striatal, cortical, nigral and subthalamic lesions. This work will be extended to investigate the hypothesis that the specific genes for GABAA and non-NMDA receptor subtypes regulate differentially after selective lesions of basal ganglia subnuclei. We will combine autoradiography of ligand binding with in situ hybridization of oligonucleotide probes for GABAA, AMPA, and metabotropic receptor subunits. We anticipate that those receptors that regulate after lesions may not be those that are predominantly expressed under normal conditions. Elucidation of the details of receptor regulation in these animal models of Huntington's disease, Parkinson's disease, dystonia, and hemiballismus will allow us to devise more effective pharmacotherapies for these illnesses using drugs selective for the various receptor subtypes. Such studies will also add to the understanding of basal ganglia circuitry in health and disease.
基底神经节在控制正常运动中起着重要作用

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John B Penney其他文献

John B Penney的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John B Penney', 18)}}的其他基金

SELECTIVE VULNERABILITY OF DOPAMINE NEURONS IN PARKINSON'S DISEASE
帕金森病中多巴胺神经元的选择性脆弱性
  • 批准号:
    6347674
  • 财政年份:
    2000
  • 资助金额:
    $ 18.4万
  • 项目类别:
CORE--TRAINING AND CLINICAL FACILITY
核心——培训和临床设施
  • 批准号:
    6347676
  • 财政年份:
    2000
  • 资助金额:
    $ 18.4万
  • 项目类别:
SELECTIVE VULNERABILITY OF DOPAMINE NEURONS IN PARKINSON'S DISEASE
帕金森病中多巴胺神经元的选择性脆弱性
  • 批准号:
    6219191
  • 财政年份:
    1999
  • 资助金额:
    $ 18.4万
  • 项目类别:
CORE--TRAINING AND CLINICAL FACILITY
核心——培训和临床设施
  • 批准号:
    6219193
  • 财政年份:
    1999
  • 资助金额:
    $ 18.4万
  • 项目类别:
CORE--TRAINING AND CLINICAL FACILITY
核心——培训和临床设施
  • 批准号:
    6112671
  • 财政年份:
    1998
  • 资助金额:
    $ 18.4万
  • 项目类别:
SELECTIVE VULNERABILITY OF DOPAMINE NEURONS IN PARKINSON'S DISEASE
帕金森病中多巴胺神经元的选择性脆弱性
  • 批准号:
    6273955
  • 财政年份:
    1998
  • 资助金额:
    $ 18.4万
  • 项目类别:
MGH/MIT PARKINSONS DISEASE RESEARCH CENTER
麻省总医院/麻省理工学院帕金森病研究中心
  • 批准号:
    6040964
  • 财政年份:
    1998
  • 资助金额:
    $ 18.4万
  • 项目类别:
SELECTIVE VULNERABILITY OF DOPAMINE NEURONS IN PARKINSON'S DISEASE
帕金森病中多巴胺神经元的选择性脆弱性
  • 批准号:
    6112669
  • 财政年份:
    1998
  • 资助金额:
    $ 18.4万
  • 项目类别:
MGH/MIT PARKINSONS DISEASE RESEARCH CENTER
麻省总医院/麻省理工学院帕金森病研究中心
  • 批准号:
    2791036
  • 财政年份:
    1998
  • 资助金额:
    $ 18.4万
  • 项目类别:
CORE--TRAINING AND CLINICAL FACILITY
核心——培训和临床设施
  • 批准号:
    6273957
  • 财政年份:
    1998
  • 资助金额:
    $ 18.4万
  • 项目类别:

相似海外基金

Exploring the role of epigenetic mechanisms in the manifestation of Huntington's disease
探索表观遗传机制在亨廷顿舞蹈病表现中的作用
  • 批准号:
    MR/Y014685/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.4万
  • 项目类别:
    Research Grant
Project 3: Therapeutic Gene Editing for Huntington's Disease
项目3:亨廷顿病的治疗性基因编辑
  • 批准号:
    10668769
  • 财政年份:
    2023
  • 资助金额:
    $ 18.4万
  • 项目类别:
Brain-targeted delivery of therapeutic molecules by exosomes derived from engineered human iPS cells: a potential therapeutic approach for Huntington's disease
通过源自工程化人类 iPS 细胞的外泌体向大脑靶向递送治疗分子:亨廷顿病的潜在治疗方法
  • 批准号:
    10588392
  • 财政年份:
    2023
  • 资助金额:
    $ 18.4万
  • 项目类别:
Emerging role of glymphatic clearance in Huntington's disease
类淋巴清除在亨廷顿病中的新作用
  • 批准号:
    10599627
  • 财政年份:
    2023
  • 资助金额:
    $ 18.4万
  • 项目类别:
Characterizing GABAergic transmission at the cellular and synaptic levels in the developing and mature basal ganglia of the Huntington's Disease brain
描述亨廷顿病大脑发育和成熟基底神经节细胞和突触水平上的 GABA 能传递
  • 批准号:
    478477
  • 财政年份:
    2023
  • 资助金额:
    $ 18.4万
  • 项目类别:
    Operating Grants
Using genetic modifiers to identify and target pathogenic mechanisms in Huntington's disease
使用遗传修饰剂来识别和靶向亨廷顿病的致病机制
  • 批准号:
    MR/X018253/1
  • 财政年份:
    2023
  • 资助金额:
    $ 18.4万
  • 项目类别:
    Fellowship
Repeat-induced mutagenesis in Huntington's disease
亨廷顿病的重复诱导突变
  • 批准号:
    MR/X02184X/1
  • 财政年份:
    2023
  • 资助金额:
    $ 18.4万
  • 项目类别:
    Research Grant
Elucidating Semaphorin-6D Signaling Axis in Huntington's Disease
阐明亨廷顿病中的 Semaphorin-6D 信号轴
  • 批准号:
    23K14503
  • 财政年份:
    2023
  • 资助金额:
    $ 18.4万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Modulation of Somatic Repeat Expansion as a Therapeutic Approach to Huntington's Disease
调节体细胞重复扩增作为亨廷顿病的治疗方法
  • 批准号:
    10678016
  • 财政年份:
    2023
  • 资助金额:
    $ 18.4万
  • 项目类别:
Identifying New Astrocytic Kir4.1 Channel Modulators for Treating Huntington's Disease
鉴定用于治疗亨廷顿病的新型星形细胞 Kir4.1 通道调节剂
  • 批准号:
    10681097
  • 财政年份:
    2023
  • 资助金额:
    $ 18.4万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了